#USA #Berkeley #Lilly #Prellis Biologics #biological AI

Prellis Biologics Partners with Eli Lilly for Antibody Innovation

In a significant advancement for antibody therapeutics, Prellis Biologics, Inc. has announced a collaboration with Eli Lilly and Company that aims to reshape the landscape of drug discovery. This partnership merges Prellis' innovative technology with Lilly's extensive expertise, facilitating the development of cutting-edge human antibody therapeutics across multiple disease targets.

The collaboration leverages Prellis' proprietary EXIS™ platform, which utilizes human lymph node organoids and artificial intelligence to generate high specificity antibodies rapidly. The unique attributes of this platform allow for a realistic re-enactment of the human immune response, which is pivotal in understanding how new therapies can effectively address various health issues.

Highlights of the Collaboration

Under the terms of their agreement, both companies will jointly spearhead the discovery and development of therapeutic antibodies for a selection of targets. Of particular note, the partnership is built upon Prellis' advanced organoid technology that mimics the human immune system accurately. This technology combined with their AI-based optimization approach promises enhanced efficacy, safety, and manufacturability of therapeutics.

Mike Nohaile, CEO of Prellis, emphasized the transformative nature of this collaboration, stating, "We are revolutionizing antibody discovery by integrating human biology with advanced AI. Our rapid discovery process, which typically takes just 3-4 weeks, allows us to produce diverse, high-affinity antibodies from organoids derived entirely from humans."

The Role of AI in Drug Discovery

Prellis is pioneering a new kind of biological AI that is unique in the market; rather than using just imaging technology to detect conditions, their approach intricately links live human biological systems with generative AI methodologies to facilitate drug design. This one-of-a-kind hybrid approach solves a core challenge of drug development—the lack of sufficient high-quality human data, which is essential for training AI models effectively.

The EXIS™ platform stands apart due to its ability to harness real biological systems in real-time, which facilitates continuous learning and improvements in drug viability.

Future Prospects

Dr. Les Miranda, Chief Scientific Officer at Prellis, outlined the mission behind this innovative partnership: "Our goal is to fundamentally alter the process of antibody therapy development to make it more efficient and accessible. We envision a future where biology and AI treatment methods coalesce seamlessly to tackle complex diseases decisively and rapidly."

Prellis Biologics prides itself on being the first organization to develop a fully synthetic and functioning human immune system, termed the Externalized Immune System (EXIS™). This advanced methodology allows for unmatched replication of human organ and tissue structures at an accelerated rate, fostering significant improvements in drug discovery processes.

The strategic alliance between Prellis and Lilly marks a pivotal moment in biotechnology, showcasing how innovative technologies and strategic collaborations can gather momentum to produce impactful medical advancements. With patient lives profoundly benefiting from these developments, the future shines brightly for antibody therapeutics built on cutting-edge biological research and AI technologies.

By merging these two standout capabilities, Prellis and Lilly are not just ready to enhance the efficiency of drug discovery; they are setting a new standard for the entire biopharmaceutical industry.

For detailed updates and insights, continue to follow the journey of Prellis Biologics, which is steadfastly committed to changing the paradigm of medicine and enhancing patient care around the globe.